Following a period of collaboration between its scientists, MDs, and biomedical engineers, Genetoo is now entering the development phase of a project to create bacteriophobic surfaces in prosthetic implants. About a month ago, the company licensed a patent from the National Aeronautics and Space Administration (NASA). Since then, Genetoo has formed strategic alliances with industry stakeholders and laid the groundwork for the revolutionary development phase they are now entering.
Chris Whitman, CEO of Genetoo, calls this a “pivotal point in which we want to move from level 1 directly into level 5.”
Research performed by NASA drastically reduced corporate costs and project timelines, enabling Genetoo to progress to the development phase more quickly than they would have been able to otherwise. They remain committed to demonstrating “the high value and potential” of this game-changing technology they believe will go beyond preventing infection in prosthetic implants and make it a thing of the past. A prototype is expected to be available soon.
Genetoo’s dedication to the experience of both physicians and patients is reflected in the company’s vision for this innovative technology. The resulting reduction in surface bacteria adhesion will reduce skyrocketing medical costs, reduce patient pain and complications, and create a future in which infection of an implanted prosthetic is a rarity.
While the work performed by scientists to develop protocols and SOPs is invaluable in upscaling the technology, the marketing and business development team continues to interact with customers, prosthetic manufacturers, and physicians to ensure their product meets everyone’s needs.
Please feel free to contact us if you would like to learn more about this groundbreaking technology.
